Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinicopathologic Spectrum of Renal Lesions Following Anti-TNF- α Inhibitor Therapy: A Single Center Experience.
Kidney360
March 2023
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
Article Synopsis
- This study examines kidney dysfunction and pathologic changes in patients receiving anti-TNF therapy compared to those who are not treated, revealing a range of autoimmune-related kidney problems due to the therapy.* -
- Anti-TNF inhibitors are used to treat various autoimmune diseases but can trigger adverse autoimmune serologic reactions and complications, such as vasculitis and lupus-like syndromes affecting the kidneys.* -
- A retrospective analysis of renal biopsies from patients treated with anti-TNF agents from 2000 to 2018 found diverse kidney issues, including crescentic glomerulonephritis and lupus nephritis, along with unrelated renal conditions in some patients.*
Fatal Acute Hemorrhagic Encephalomyelitis and Antiphospholipid Antibodies following SARS-CoV-2 Vaccination: A Case Report.
Vaccines (Basel)
November 2022
Department of Clinical Neuroscience, Division of Neurology, Karolinska Institute and Neurology, Karolinska University Hospital, 171 76 Stockholm, Sweden.
Article Synopsis
- Acute hemorrhagic encephalomyelitis (AHEM) is a rare and severe condition characterized by inflammation and demyelination in the central nervous system, often linked to infections or vaccinations.
- A case of a 53-year-old male with rheumatoid arthritis who developed fatal AHEM after receiving the COVID-19 vaccine is discussed, alongside complications such as thromboembolic disease and elevated antiphospholipid antibodies.
- The report emphasizes the challenges of diagnosing AHEM in patients with existing health issues and the need to monitor potential adverse effects of COVID-19 vaccinations to better protect vulnerable populations.
Drug-induced antiphospholipid syndrome: Analysis of the WHO international database.
Autoimmun Rev
May 2022
Sorbonne Université, APHP, Service de Médecine Interne, Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie (DMU i3), F-75012 Paris, France. Electronic address:
Objective: As with drug-induced lupus, some drugs may induce an antiphospholipid syndrome (APS). With the always growing numbers of new molecules, the list of the liable treatments evolves rapidly. We herein analyzed VigiBase, the international pharmacovigilance database, to identify drugs suspected of inducing APS.
View Article and Find Full Text PDFEndometriosis with infertility: A comprehensive review on the role of immune deregulation and immunomodulation therapy.
Am J Reprod Immunol
March 2021
Sorbonne Université, AP-HP, Hôpital Saint-Antoine, service de Médecine Interne and Inflammation, Paris, France.
Background: Endometriosis is a multifactorial pathology dependent on intrinsic and extrinsic factors, but the immune deregulation seems to play a pivotal role. In endometriosis-associated infertility, this could raise the benefit of immunomodulatory strategies to improve the results of ART. In this review, we will describe (1) sera and peritoneal fluid cytokines and immune markers; (2) autoantibodies; and (3) immunomodulatory treatments in endometriosis with infertility.
View Article and Find Full Text PDFAntiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.
Med Sci Monit
July 2014
Department of Rheummatology and Connective Tissue Diseases, Medical University of Lublin, Lublin, Poland.
Background: The introduction of tumor necrosis factor (TNF) antagonists (adalimumab, infliximab, and etanercept) was a major advance and was highly important and beneficial in most rheumatoid arthritis (RA) patients. The adverse effects of this treatment are infrequent, but include opportunistic intracellular infection (especially the reactivation of latent Mycobacterium tuberculosis); exacerbation of demyelinating disorders; and the production of various types of antibodies such as antinuclear antibodies (ANA) or double-stranded DNA autoantibodies (dsDNA) and antiphospholipid antibodies (aPL) such as anti-cardiolipin antibodies (aCL) and anti-B2GP-I antibodies (B2GP-I). The aim of the study was to determine the prevalence of aCL and B2GP-I in IgM and IgG classes, using ELISA tests, during 6 months of follow-up in patients with refractory RA successfully treated with infliximab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!